{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:02:36Z","timestamp":1784743356371,"version":"3.55.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Cutaneous melanoma (CM) incidence is rising, and despite advances in immune checkpoint inhibitors (ICI), many metastatic patients do not respond or develop resistance. This study aimed to evaluate the prognostic value of a pre-treatment FDG-PET\/CT-based radiomic model (MEL-RAD) for predicting 1-year progression-free survival (1y-PFS) in metastatic CM patients treated with first-line ICI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively included 154 metastatic CM patients from two centers who underwent pre-treatment FDG-PET\/CT before ICI initiation. Patients were split into a development cohort (n=95) and an independent testing cohort (n=59). Radiomic features were extracted and harmonized to reduce inter-cohort variability. A two-step feature selection identified three key wavelet-transformed texture features used to build the MEL-RAD predictive model. The model\u2019s performance was assessed by receiver operating characteristic (ROC) analysis, sensitivity, specificity, and predictive values. Survival analyses (progression-free (PFS) and overall survival (OS)) were performed with Cox regression and Kaplan-Meier methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the development cohort, MEL-RAD achieved an AUC of 0.74 (p&amp;lt;0.0001) for predicting 1y-PFS. Using a 55% probability threshold, sensitivity was 93.8%, specificity 31.9%, with positive and negative predictive values of 58.4% and 83.4%, respectively. Patients with MEL-RAD &amp;gt;55% had significantly worse PFS (HR = 2.73, p=0.0009) and OS (HR = 3.20, p=0.0003). These results were externally validated: in the testing cohort, MEL-RAD positivity remained significantly associated with poorer PFS (HR = 2.73, p=0.047), and showed non-significant for OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The MEL-RAD radiomic model based on pre-treatment FDG-PET\/CT offers a non-invasive biomarker to stratify metastatic CM patients treated with immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1642620","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:32:52Z","timestamp":1771997572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["18F-FDG PET radiomic analysis to predict outcomes in metastatic melanoma treated with immune checkpoint inhibitors"],"prefix":"10.3389","volume":"17","author":[{"given":"Karim","family":"Amrane","sequence":"first","affiliation":[{"name":"Department of Oncology, Regional Hospital of Morlaix","place":["Morlaix, France"]},{"name":"LBAI, UMR1227, Univ Brest, Inserm","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline","family":"Le Meur","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Hospital of Brest","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bourhis","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital of Brest","place":["Brest, France"]},{"name":"UMR Inserm 1304 GETBO, IFR 148, University of Western Brittany","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Berthou","sequence":"additional","affiliation":[{"name":"LBAI, UMR1227, Univ Brest, Inserm","place":["Brest, France"]},{"name":"Department of Hematology, University Hospital of Brest","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Pradier","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Hospital of Brest","place":["Brest, France"]},{"name":"Inserm, UMR1101, LaTIM, University of Western Brittany","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Misery","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Brest","place":["Brest, France"]},{"name":"Laboratoire sur les Interactions \u00c9pith\u00e9liums-Neurones (LIEN-EA4685), University of Western Brittany","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Legoupil","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Brest","place":["Brest, France"]},{"name":"Laboratoire sur les Interactions \u00c9pith\u00e9liums-Neurones (LIEN-EA4685), University of Western Brittany","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Etienne","sequence":"additional","affiliation":[{"name":"Department of Dermatology Centre Hospitalier de Cornouaille","place":["Quimper, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges-Philippe","family":"Fontaine","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Centre Georges Charpak","place":["Quimper, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Leleu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Centre Hospitalier de Cornouaille","place":["Quimper, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Floch","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital of Brest","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Salaun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital of Brest","place":["Brest, France"]},{"name":"UMR Inserm 1304 GETBO, IFR 148, University of Western Brittany","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Abgral","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital of Brest","place":["Brest, France"]},{"name":"UMR Inserm 1304 GETBO, IFR 148, University of Western Brittany","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bourbonne","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Hospital of Brest","place":["Brest, France"]},{"name":"Inserm, UMR1101, LaTIM, University of Western Brittany","place":["Brest, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9040063","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B2","doi-asserted-by":"crossref","unstructured":"Overall survival in patients with metastatic melanoma\n          \n          987\n          91\n          \n            \n              Song\n              X\n            \n            \n              Zhao\n              Z\n            \n            \n              Barber\n              B\n            \n            \n              Farr\n              AM\n            \n            \n              Ivanov\n              B\n            \n            \n              Novich\n              M\n            \n          \n          10.1185\/03007995.2015.1021904\n          25708472\n          Curr Med Res Opin\n          31\n          2015","DOI":"10.1185\/03007995.2015.1021904"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00995","article-title":"Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma","volume":"38","author":"Robert","year":"2020","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e000948","DOI":"10.1136\/jitc-2020-000948","article-title":"Evolving impact of long-term survival results on metastatic melanoma treatment","volume":"8","author":"Michielin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1285895","article-title":"HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker","author":"Amrane","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40644-024-00732-5","article-title":"Review on radiomic analysis in 18F-fluorodeoxyglucose positron emission tomography for prediction of melanoma outcomes","volume":"24","author":"Amrane","year":"2024","journal-title":"Cancer Imaging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","article-title":"Good clinical practice recommendations for the use of PET\/CT in oncology","volume":"47","author":"Sala\u00fcn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.12.020","article-title":"ECCO essential requirements for quality cancer care: Melanoma","volume":"122","author":"Wouters","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103044","article-title":"Rational use of 18F-FDG PET\/CT in patients with advanced cutaneous melanoma: A systematic review","volume":"153","author":"Bisschop","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3427-0","article-title":"Characterization of PET\/CT images using texture analysis: the past, the present \u2026 any future","volume":"44","author":"Hatt","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.05.022","article-title":"Radiomics in nuclear medicine applied to radiation therapy: methods, pitfalls, and challenges","volume":"102","author":"Reuz\u00e9","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2020.09.002","article-title":"Radiomics in PET\/CT: current status and future AI-based evolutions","volume":"51","author":"Hatt","year":"2021","journal-title":"Semin Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116132","article-title":"Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review","volume":"233","author":"Soon","year":"2026","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02347","article-title":"De-escalation strategies with immune checkpoint blockers in non-small cell lung cancer: do we already have enough evidence","volume":"43","author":"Remon","year":"2025","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e221180","DOI":"10.1148\/radiol.221180","article-title":"FDG PET\/CT prognostic markers in patients with advanced melanoma treated with ipilimumab and nivolumab","volume":"307","author":"Iravani","year":"2023","journal-title":"Radiology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2017.11.024","article-title":"Harmonization of cortical thickness measurements across scanners and sites","volume":"167","author":"Fortin","year":"2018","journal-title":"NeuroImage"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.09.008","article-title":"Development and prospective validation of a spatial dose pattern based model predicting acute pulmonary toxicity in patients treated with volumetric arc-therapy for locally advanced lung cancer","volume":"164","author":"Bourbonne","year":"2021","journal-title":"Radiother Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.10.040","article-title":"Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer","volume":"155","author":"Bourbonne","year":"2021","journal-title":"Radiother Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10555-023-10097-z","article-title":"Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better","volume":"42","author":"Haist","year":"2023","journal-title":"Cancer Metastasis Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1055\/a-1140-5458","article-title":"Textural features in FDG-PET\/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab","volume":"59","author":"Dittrich","year":"2020","journal-title":"Nuklearmedizin"},{"key":"B28","doi-asserted-by":"publisher","first-page":"18795","DOI":"10.1038\/s41598-021-98310-3","article-title":"FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy","volume":"11","author":"Flaus","year":"2021","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.977822","article-title":"Outcome prediction at patient level derived from pre-treatment 18F-FDG PET due to machine learning in metastatic melanoma treated with anti-PD1 treatment","volume":"12","author":"Flaus","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04967-9","article-title":"The value of 18F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis","volume":"48","author":"Ayati","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fradi.2023.1240544","article-title":"Spatial assessments in texture analysis: what the radiologist needs to know","volume":"3","author":"Varghese","year":"2023","journal-title":"Front Radiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e95335","DOI":"10.7759\/cureus.95335","article-title":"Radiomics and the image biomarker standardisation initiative (IBSI): A narrative review using a six-question map and implementation framework for reproducible imaging biomarkers","volume":"17","author":"Aguirre-Meneses","year":"2025","journal-title":"Cureus"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.222893","article-title":"Introduction to radiomics","volume":"61","author":"Mayerhoefer","year":"2020","journal-title":"J Nucl Med"},{"key":"B35","article-title":"Prognostic value of genetic alterations and 18F-FDG PET\/CT imaging features in diffuse large B cell lymphoma","volume":"13","author":"Ferrer-Lores","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41523-018-0078-2","article-title":"Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis","volume":"4","author":"Huang","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2022.2108827","article-title":"Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis","volume":"40","author":"Kamat","year":"2022","journal-title":"Cancer Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3716","article-title":"Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases","volume":"10","author":"Moyers","year":"2021","journal-title":"Cancer Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1237643","article-title":"Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1","volume":"13","author":"Janka","year":"2023","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-012-2280-z","article-title":"Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours","volume":"40","author":"Van de Wiele","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0214299","DOI":"10.1371\/journal.pone.0214299","article-title":"Inter-observer and segmentation method variability of textural analysis in pre-therapeutic FDG PET\/CT in head and neck cancer","volume":"14","author":"Guezennec","year":"2019","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13550-017-0279-y","article-title":"Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs)","volume":"7","author":"Lasnon","year":"2017","journal-title":"EJNMMI Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better","volume":"52","author":"Im","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109242","article-title":"CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases","volume":"131","author":"Olthof","year":"2020","journal-title":"Eur J Radiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2967\/jnumed.111.099127","article-title":"Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET","volume":"53","author":"Tixier","year":"2012","journal-title":"J Nucl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"jnumed.123.266749","DOI":"10.2967\/jnumed.123.266749","article-title":"PET\/CT-based radiogenomics supports KEAP1\/NFE2L2 pathway targeting for non-small cell lung cancer treated with curative radiotherapy","author":"Bourbonne","year":"2024","journal-title":"J Nucl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.radonc.2018.10.027","article-title":"Vulnerabilities of radiomic signature development: The need for safeguards","volume":"130","author":"Welch","year":"2019","journal-title":"Radiother Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41698-024-00534-9","article-title":"A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking","volume":"8","author":"Ligero","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/aba798","article-title":"Harmonization strategies for multicenter radiomics investigations","author":"Da-Ano","year":"2020","journal-title":"Phys Med Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2023.05.023","article-title":"Evaluating prediction model performance","volume":"174","author":"Cabot","year":"2023","journal-title":"Surgery"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001543","article-title":"Radiomics: a quantitative imaging biomarker in precision oncology","volume":"43","author":"Jha","year":"2022","journal-title":"Nucl Med Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1642620\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:32:57Z","timestamp":1771997577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1642620\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2026.1642620"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1642620","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1642620"}}